A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer.
Triple-Negative Breast Cancer
DRUG: 9MW2821|DRUG: PD-1 inhibitior
Objective Response Rate, ORR, Up to 24 months
Duration of Response, DoR, Up to 24 months|Time to Response, TTR, Up to 24 months|Disease Control Rate, DCR, Up to 24 months|Progression Free Survival, PFS, Up to 24 months|Overall Survival, OS, Up to 24 months|Pharmacokinetic parameter：total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE), Maximum observed concentration (Cmax), 24 months|Pharmacokinetic parameter：total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE), Area under the concentration-time curve (AUC), 24 months|Pharmacokinetic parameter：total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE), Half-life (t1/2), 24 months|Pharmacokinetic parameter：total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE), Clearance (CL), 24 months|Incidence of Anti-Drug Antibody (ADA), ADA, Up to 24 months
This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer.